Paliperidone

UZEDY is currently approved in the US as a subcutaneous long-acting injectable (LAI) for use every one or two months for the treatment of schizophrenia in adults 1 LAI treatment options may help address unmet needs of people living with bipolar I disorder (BP-I) BP-I filing acceptance for UZEDY represents Teva’s commitment to pursuing new advances in neuroscience PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL) announced today that the supplemental New Drug Application (sNDA) for UZEDY extended-release injectable suspension for the maintenance treatment of BP-I in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA). The sNDA is based on leveraging the existing clinical data for UZEDY coupled with the Agency’s previous findings of safety and efficacy of past risperidone formulations approved for the treatment of BP-I. “Since the FDA approval of UZEDY almost two years ago, it has proven to be an important treatment option for people living with schizophrenia,” said Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer at Teva. “Today’s filing demonstrates the potential of UZEDY’s clinical pro a long-acting treatment for bipolar-I, a complex mental health disorder that significantly affects a person’s mood, behavior, and overall state of mind. Debilitating manic and depressive symptoms and signs can also occur.” Teva will lead the regulatory process and be responsible for potential commercialization of UZEDY for BP-I, with Medincell eligible for royalties on net sales. “Long-acting injectables are key drivers of innovation in the CNS field today,” said Dr. Richard Malamut, Chief Medical Officer at Medincell. “In bipolar I disorder, as in schizophrenia, nonadherence remains a major barrier to effective care, one that UZEDY has the potential to help. We are proud to partner with Teva to deliver treatment options aimed at meeting unmet medical needs.” UZEDY was approved in the U.S. for the treatment of schizophrenia in adults in 2023. 2 The efficacy and long-term safety and tolerability of UZEDY for the treatment of schizophrenia have been evaluated in two Phase 3 pivotal studies: TV46000-CNS-30072 (the RISE Study – The Risperidone Subcutaneous Extended-Release Study) 3 and TV46000-CNS-30078 (the SHINE Study – Safety in Humans of TV-46000 sc INjection Evaluation) 2 . The safety and efficacy of UZEDY for BP-I are not established and UZEDY is not approved by any regulatory authority for this indication. About Bipolar I Disorder Bipolar Disorder I (BP-I) is a manic-depressive condition that leads to large swings in mood and actions that greatly impact quality of life and ability to complete day-to-day tasks. It is challenging to diagnose and is often accompanied by other psychiatric comorbidities. BP-I is associated with poor long-term outcomes and a substantial increase in mortality compared to the general population from both suicide and cardiovascular disease. An estimated 1% or 3,400,000+ of U.S. adults will develop BP-I in their lifetime. 4 About the RISE Study RISE, Teva’s Phase 3 study, was a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of risperidone extended-release injectable suspension for subcutaneous use as a treatment in patients (ages 13-65 years) with schizophrenia. 3 544 patients were randomized to receive a subcutaneous injection of UZEDY once monthly (q1M), once every two months (q2M), or placebo in a 1:1:1 ratio. The primary endpoint was time to impending relapse. 3 About the SHINE Study The second of Teva’s Phase 3 studies; designed to evaluate the long-term safety, tolerability and effectof UZEDY subcutaneously administered q1M or q2M for up to 56 weeks in 331 patients (ages 13-65 years) with schizophrenia. The primary endpoint was the frequency of all adverse events, including serious adverse events. 2 About UZEDY UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for the treatment of schizophrenia in adults. In clinical trials, UZEDY significantly reduced the risk of schizophrenia relapse. 1, 2 UZEDY administers risperidone through copolymer technology under license from Medincell that allows for absorption and sustained release after subcutaneous injection. UZEDY is the only long-acting, subcutaneous formulation of risperidone available in both one- and two-month dosing intervals. 1 For full prescribing information, visit . INDICATION AND USAGE UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for the treatment of schizophrenia in adults. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. UZEDY is not approved for use in patients with dementia-related psychosis and has not been studied in this patient population. See below for additional Important Safety Information. IMPORTANT SAFETY INFORMATION CONTINUED CONTRAINDICATIONS: UZEDY is contraindicated in patients with a known hypersensitivity to risperidone, its metabolite, paliperidone, or to any of its components. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone or paliperidone. WARNINGS AND PRECAUTIONS Cerebrovascular Adverse Reactions: In trials of elderly patients with dementia-related psychosis, there was a significantly higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, in patients treated with oral risperidone compared to placebo. UZEDY is not approved for use in patients with dementia-related psychosis. Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported in association with antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status including delirium, and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. If NMS is suspected, immediately discontinue UZEDY and provide symptomatic treatment and monitoring. Tardive Dyskinesia (TD): TD, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to predict which patients will develop the syndrome. Whether antipsychotic drug products differ in their potential to cause TD is unknown. The risk of developing TD and the likelihood that it will become irreversible are believed to increase with the duration of treatment and the cumulative dose. The syndrome can develop, after relatively brief treatment periods, even at low doses. It may also occur after discontinuation. TD may remit, partially or completely, if antipsychotic treatment is discontinued. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome, possibly masking the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. If signs and symptoms of TD appear in a patient treated with UZEDY, drug discontinuation should be considered. However, some patients may require treatment with UZEDY despite the presence of the syndrome. In patients who do require chronic treatment, use the lowest dose and the shortest duration of treatment producing a satisfactory clinical response. Periodically reassess the need for continued treatment. Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain. While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile. Hyperglycemia and diabetes mellitus (DM): in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, have been reported in patients treated with atypical antipsychotics, including risperidone. Patients with an established diagnosis of DM who are started on atypical antipsychotics, including UZEDY, should be monitored regularly for worsening of glucose control. Patients with risk factors for DM (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics, including UZEDY, should undergo fasting blood glucose (FBG) testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics, including UZEDY, should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics, including UZEDY, should undergo FBG testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic, including risperidone, was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of risperidone. Dyslipidemia has been observed in patients treated with atypical antipsychotics. Weight gain has been observed with atypical antipsychotic use. Monitoring weight is recommended. Hyperprolactinemia: As with other drugs that antagonize dopamine D 2 receptors, risperidone elevates prolactin levels and the elevation persists during chronic administration. Risperidone is associated with higher levels of prolactin elevation than other antipsychotic agents. Orthostatic Hypotension and Syncope: UZEDY may induce orthostatic hypotension associated with dizziness, tachycardia, and in some patients, syncope. UZEDY should be used with particular caution in patients with known cardiovascular disease, cerebrovascular disease, and conditions which would predispose patients to hypotension and in the elderly and patients with renal or hepatic impairment. Monitoring of orthostatic vital signs should be considered in all such patients, and a dose reduction should be considered if hypotension occurs. Clinically significant hypotension has been observed with concomitant use of oral risperidone and antihypertensive medication. Falls: Antipsychotics, including UZEDY, may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other fall-related injuries. Somnolence, postural hypotension, motor and sensory instability have been reported with the use of risperidone. For patients, particularly the elderly, with diseases, conditions, or medications that could exacerbate these effects, assess the risk of falls when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy. Leukopenia, Neutropenia, and Agranulocytosis have been reported with antipsychotic agents, including risperidone. In patients with a pre-existing history of a clinically significant low white blood cell count (WBC) or absolute neutrophil count (ANC) or a history of drug-induced leukopenia or neutropenia, perform a complete blood count (CBC) frequently during the first few months of therapy. In such patients, consider discontinuation of UZEDY at the first sign of a clinically significant decline in WBC in the absence of other causative factors. Monitor patients with clinically significant neutropenia for fever or other symptoms or signs of infection and treat promptly if such symptoms or signs occur. Discontinue UZEDY in patients with ANC < 1000/mm 3 ) and follow their WBC until recovery. Potential for Cognitive and Motor Impairment: UZEDY, like other antipsychotics, may cause somnolence and has the potential to impair judgement, thinking, and motor skills. Somnolence was a commonly reported adverse reaction associated with oral risperidone treatment. Caution patients about operating hazardous machinery, including motor vehicles, until they are reasonably certain that treatment with UZEDY does not affect them adversely. Seizures: During premarketing studies of oral risperidone in adult patients with schizophrenia, seizures occurred in 0.3% of patients (9 out of 2,607 patients), two in association with hyponatremia. Use UZEDY cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold. Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Antipsychotic drugs, including UZEDY, should be used cautiously in patients at risk for aspiration. Priapism has been reported during postmarketing surveillance for other risperidone products. A case of priapism was reported in premarket studies of UZEDY. Severe priapism may require surgical intervention. Body temperature regulation . Disruption of the body’s ability to reduce core body temperature has been attributed to antipsychotic agents. Both hyperthermia and hypothermia have been reported in association with oral risperidone use. Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use UZEDY with caution in patients who experience these conditions. ADVERSE REACTIONS The most common adverse reactions with risperidone (≥5% and greater than placebo) were parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, increased weight, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, and pharyngolaryngeal pain. The most common injection site reactions with UZEDY (≥5% and greater than placebo) were pruritus and nodule. DRUG INTERACTIONS Carbamazepine and other strong CYP3A4 inducers decrease plasma concentrations of risperidone. Fluoxetine, paroxetine, and other strong CYP2D6 inhibitors increase risperidone plasma concentration. Due to additive pharmacologic effects, the concomitant use of centrally-acting drugs, including alcohol, may increase nervous system disorders. UZEDY may enhance the hypotensive effects of other therapeutic agents with this potential. UZEDY may antagonize the pharmacologic effects of dopamine agonists. Concomitant use with methylphenidate, when there is change in dosage of either medication, may increase the risk of extrapyramidal symptoms (EPS) USE IN SPECIFIC POPULATIONS Pregnancy: May cause EPS and/or withdrawal symptoms in neonates with third trimester exposure. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including UZEDY, during pregnancy. Healthcare providers are encouraged to register patients by contacting the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or online at . Lactation: Infants exposed to risperidone through breastmilk should be monitored for excess sedation, failure to thrive, jitteriness, and EPS. Fertility: UZEDY may cause a reversible reduction in fertility in females. Pediatric Use: Safety and effectiveness of UZEDY have not been established in pediatric patients. Renal or Hepatic Impairment: Carefully titrate on oral risperidone up to at least 2 mg daily before initiating treatment with UZEDY. Patients with Parkinson’s disease or dementia with Lewy bodies can experience increased sensitivity to UZEDY. Manifestations and features are consistent with NMS. Please see the full Prescribing Information for UZEDY, including Boxed WARNING. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global pharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. If patients have a need, we’re already working to address it. To learn more about how Teva is all in for better health, visit . Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize UZEDY (risperidone) extended-release injectable suspension for the maintenance treatment of BP-I in adult patients; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generic medicines; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned “Risk Factors and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. UZEDY® (risperidone) extended-release injectable suspension, for subcutaneous injection Current Prescribing Information. Parsippany, NJ. Teva Neuroscience, Inc. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. Clinicaltrials.gov. Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia (RISE). Accessed November 2024. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2007;64(5):543–552. doi:10.1001/archpsyc.64.5.543 Teva Media Inquiries: TevaCommunicationsNorthAmerica@tevapharm.com Teva Investor Relations Inquires TevaIR@Tevapharm.com About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. Contact: communication@medincell.com

统计每周仿制药一致性评价申报、上市申请（2.10-2.16）  1、仿制药上市申请获批药品名称企业名称分类受理号艾普拉唑肠溶片石药集团中诺药业（石家庄）有限公司4CYHS2302674贝前列素钠片浙江仙琚制药股份有限公司4CYHS2302791波生坦片Mylan S.p.A.5.2JYHS2200026波生坦片Mylan S.p.A.5.2JYHS2200025达格列净二甲双胍缓释片（Ⅰ）齐鲁制药有限公司4CYHS2303369达格列净二甲双胍缓释片（Ⅲ）齐鲁制药有限公司4CYHS2303370蛋白琥珀酸铁口服溶液山东则正医药技术有限公司;华益泰康药业股份有限公司4CYHS2404465多索茶碱注射液浙江昂利康制药股份有限公司;浙江创新生物有限公司4CYHS2303331二羟丙茶碱注射液海南紫程众投生物科技有限公司;河北凯威制药有限责任公司3CYHS2302596氟脲嘧啶注射液湖北民康药业集团有限公司;天津金耀药业有限公司3CYHS2301235氟脲嘧啶注射液湖北民康药业集团有限公司;天津金耀药业有限公司3CYHS2301234复方聚乙二醇电解质散(III)北京北陆药业股份有限公司4CYHS2302119复方托吡卡胺滴眼液四川禾亿制药有限公司4CYHS2302682加巴喷丁胶囊上海理想制药有限公司4CYHS2303160加巴喷丁胶囊上海理想制药有限公司4CYHS2303161甲苯磺酸艾多沙班片北京百奥药业有限责任公司;江苏永安制药有限公司4CYHS2302696甲苯磺酸艾多沙班片北京百奥药业有限责任公司;江苏永安制药有限公司4CYHS2302698甲苯磺酸艾多沙班片北京百奥药业有限责任公司;江苏永安制药有限公司4CYHS2302697拉考沙胺口服液南京斯泰尔医药科技有限公司;南京海纳制药有限公司4CYHS2301796利丙双卡因乳膏广州朗圣药业有限公司4CYHS2301791硫酸氨基葡萄糖胶囊江苏诚康药业有限公司4CYHS2303418硫酸氨基葡萄糖胶囊安徽正药医药科技有限公司;华益药业科技（安徽）有限公司4CYHS2302541硫酸镁钠钾口服用浓溶液山东齐都药业有限公司;浙江赛默制药有限公司4CYHS2302980硫酸羟氯喹片重庆博腾药业有限公司4CYHS2401175硫酸沙丁胺醇口服溶液安徽四环科宝制药有限公司3CYHS2301825罗沙司他胶囊湖南先施制药有限公司;湖南九典制药股份有限公司4CYHS2302841罗沙司他胶囊湖南先施制药有限公司;湖南九典制药股份有限公司4CYHS2302842洛索洛芬钠凝胶贴膏南京海纳医药科技股份有限公司;南京海纳制药有限公司4CYHS2300523孟鲁司特钠咀嚼片恒昌（广州）新药研究有限公司;南京海纳制药有限公司4CYHS2200431孟鲁司特钠咀嚼片恒昌（广州）新药研究有限公司;南京海纳制药有限公司4CYHS2200432乳果糖口服溶液重庆健能医药开发有限公司;四川健能制药有限公司4CYHS2302716乳果糖口服溶液重庆健能医药开发有限公司;四川健能制药有限公司4CYHS2302715乳果糖口服溶液湖北凯纳药业有限公司;湖北美思创药业有限公司4CYHS2302303乳果糖口服溶液济南康桥医药科技有限公司;湖南嘉恒制药有限公司4CYHS2301566乳果糖口服溶液济南康桥医药科技有限公司;湖南嘉恒制药有限公司4CYHS2301565乳果糖口服溶液济南康桥医药科技有限公司;湖南嘉恒制药有限公司4CYHS2301567乳果糖口服溶液澳诺（中国）制药有限公司4CYHS2301513羧甲司坦口服溶液北京沃邦医药科技有限公司;扬州市三药制药有限公司3CYHS2301670他氟前列素滴眼液苏州欧康维视生物科技有限公司4CYHS2303225头孢泊肟酯片山东润泽制药有限公司4CYHS2302538头孢唑肟钠氯化钠注射液苏州大冢制药有限公司4CYHS2303615维生素B12滴眼液南京海科瑞医药科技有限公司;亚邦医药股份有限公司4CYHS2302588吸入用乙酰半胱氨酸溶液洋浦京泰药业有限公司;内蒙古白医制药股份有限公司4CYHS2301051盐酸氨溴索口服溶液江苏开元药业有限公司;江苏贝佳制药有限公司4CYHS2302901盐酸奥洛他定滴眼液深圳万和制药有限公司4CYHS2302759盐酸托莫西汀胶囊山东新时代药业有限公司4CYHS2303484盐酸左沙丁胺醇雾化吸入溶液山东京卫制药有限公司3CYHS2303106盐酸左西替利嗪口服溶液重庆华邦胜凯制药有限公司;湖南科伦制药有限公司3CYHS2302308盐酸左西替利嗪口服溶液重庆华邦胜凯制药有限公司;湖南科伦制药有限公司3CYHS2302307依折麦布阿托伐他汀钙片(Ⅱ)北京福元医药股份有限公司4CYHS2303532注射用厄他培南钠安徽省先锋制药有限公司4CYHS2301511注射用哌拉西林钠湖南柏齐鹤药物研发有限公司;江苏海宏制药有限公司3CYHS2302423 注：灰色字体部分受理号结论为不批准。 2、一致性评补充申请获批药品名称企业名称受理号酒石酸美托洛尔注射液远大医药（中国）有限公司CYHB2450249头孢克洛分散片安徽安科恒益药业有限公司CYHB2450070头孢克洛分散片安徽安科恒益药业有限公司CYHB2450071 注：灰色字体部分受理号结论为不批准。 3、新增仿制药上市申请药品名称企业名称类型受理号阿帕他胺片浙江诺得药业有限公司4CYHS2500670艾曲泊帕乙醇胺干混悬剂郑州泰丰制药有限公司3CYHS2500700氨磺必利口服溶液南京恒道医药科技股份有限公司;南京集萃剂鼎医药有限公司3CYHS2500712奥卡西平片浙江恒研医药科技有限公司;浙江赛默制药有限公司4CYHS2500740奥卡西平片浙江恒研医药科技有限公司;浙江赛默制药有限公司4CYHS2500741奥硝唑注射液四环医药（郑州）有限公司3CYHS2500705奥硝唑注射液四环医药（郑州）有限公司3CYHS2500706比拉斯汀口腔崩解片珠海市汇通达医药有限公司;珠海润都制药股份有限公司3CYHS2500717玻璃酸钠滴眼液江苏万高药业股份有限公司4CYHS2500709玻璃酸钠滴眼液江苏万高药业股份有限公司4CYHS2500710布美他尼注射液江西人可医药科技有限公司;裕松源药业有限公司3CYHS2500701布美他尼注射液江西人可医药科技有限公司;裕松源药业有限公司3CYHS2500702布瑞哌唑片重庆圣华曦药业股份有限公司4CYHS2500688布瑞哌唑片重庆圣华曦药业股份有限公司4CYHS2500689布瑞哌唑片江苏康缘药业股份有限公司4CYHS2500650布瑞哌唑片江苏康缘药业股份有限公司4CYHS2500649布瑞哌唑片江苏康缘药业股份有限公司4CYHS2500651达格列净二甲双胍缓释片（Ⅰ）江苏安必生制药有限公司4CYHS2500703低钙腹膜透析液(乳酸盐-G1.5%)辰欣药业股份有限公司4CYHS2500679低钙腹膜透析液(乳酸盐-G2.5%)辰欣药业股份有限公司4CYHS2500680二硫化硒洗剂杭州和泽坤元药业有限公司;浙江鼎泰药业股份有限公司3CYHS2500720二羟丙茶碱注射液成都华宇制药有限公司3CYHS2500730夫西地酸乳膏杭州朱养心药业有限公司4CYHS2500711复方聚乙二醇(3350)电解质口服液广州一品红制药有限公司3CYHS2500723复方聚乙二醇电解质散（儿童型）山东益康药业股份有限公司3CYHS2500725复合磷酸氢钾注射液成都诺和晟鸿生物制药有限公司;广东星昊药业有限公司3CYHS2500728富马酸伏诺拉生片浙江恒研医药科技有限公司;浙江赛默制药有限公司4CYHS2500637富马酸伏诺拉生片浙江恒研医药科技有限公司;浙江赛默制药有限公司4CYHS2500636枸橼酸莫沙必利片福建省宝诺医药研发有限公司;浙江京新药业股份有限公司4CYHS2500695枸橼酸托法替布缓释片宁波美诺华天康药业有限公司4CYHS2500648琥珀酸亚铁片江西泰吉立生物医药科技有限公司;浙江赛默制药有限公司3CYHS2500733甲磺酸仑伐替尼胶囊山东鲁抗医药股份有限公司4CYHS2500742甲磺酸沙芬酰胺片常州四药制药有限公司4CYHS2500735甲磺酸沙芬酰胺片常州四药制药有限公司4CYHS2500736精氨酸布洛芬颗粒湖北亨迪药业股份有限公司4CYHS2500726精氨酸布洛芬颗粒湖北亨迪药业股份有限公司4CYHS2500727酒石酸西尼必利片安徽佳和药业有限公司4CYHS2500676克立硼罗软膏四川科伦药业股份有限公司;广东科泓药业有限公司4CYHS2500681利格列汀片江苏康缘药业股份有限公司4CYHS2500690联苯苄唑溶液安徽四环科宝制药有限公司3CYHS2500716硫酸艾沙康唑胶囊江苏奥赛康药业有限公司4CYHS2500665硫酸氨基葡萄糖胶囊山东康林医药有限公司;以岭万洲国际制药有限公司4CYHS2500661硫酸特布他林口服溶液山东致泰医药技术有限公司;安徽新世纪药业有限公司3CYHS2500699罗沙司他胶囊浙江贝得药业有限公司4CYHS2500662罗沙司他胶囊浙江贝得药业有限公司4CYHS2500663美阿沙坦钾片珠海润都制药股份有限公司4CYHS2500694美阿沙坦钾片陕西白鹿制药股份有限公司4CYHS2500683美阿沙坦钾片陕西白鹿制药股份有限公司4CYHS2500682美沙拉秦肠溶缓释胶囊成都倍特药业股份有限公司3CYHS2500660莫匹罗星软膏国药控股鑫烨（湖北）医药有限公司;湖北广济药业股份有限公司4CYHS2500704帕利哌酮缓释片北大医药股份有限公司4CYHS2500647帕利哌酮缓释片北大医药股份有限公司4CYHS2500646普拉洛芬滴眼液重庆药谷制药有限公司;杭州民生药业股份有限公司4CYHS2500666瑞舒伐他汀依折麦布片（I）齐鲁制药（海南）有限公司4CYHS2500652瑞舒伐他汀依折麦布片（I）四川科伦药业股份有限公司4CYHS2500684赛洛多辛胶囊江苏联环药业股份有限公司4CYHS2500739沙库巴曲缬沙坦钠片苏州中化药品工业有限公司4CYHS2500664沙库巴曲缬沙坦钠片山东普瑞曼药业有限公司4CYHS2500669山梨醇甘露醇冲洗液青岛奥瑞森医疗科技有限公司;青岛瑞奈医疗科技有限公司3CYHS2500672双黄连口服液云南楚雄天利药业有限公司4CYZS2500002双嘧达莫片四川天杏汇医药科技有限公司;成都第一制药有限公司3CYHS2500691他克莫司胶囊江西远超医药科技有限公司;江苏和晨药业有限公司4CYHS2500656他克莫司胶囊北京以岭生物工程技术有限公司4CYHS2500667他克莫司胶囊江西远超医药科技有限公司;江苏和晨药业有限公司4CYHS2500655他克莫司胶囊北京以岭生物工程技术有限公司4CYHS2500668头孢妥仑匹酯颗粒苏州盛达药业有限公司;苏州第三制药厂有限责任公司4CYHS2500696头孢妥仑匹酯颗粒苏州盛达药业有限公司;苏州第三制药厂有限责任公司4CYHS2500697乌美溴铵维兰特罗吸入粉雾剂正大天晴药业集团股份有限公司4CYHS2500678硝酸甘油注射液广州合和医药有限公司;中山万汉制药有限公司3CYHS2500719硝酸甘油注射液广州合和医药有限公司;中山万汉制药有限公司3CYHS2500718硝酸甘油注射液江西人可医药科技有限公司;四川宏明博思药业有限公司3CYHS2500713硝酸甘油注射液江西人可医药科技有限公司;四川宏明博思药业有限公司3CYHS2500714小儿法罗培南钠颗粒浙江普洛康裕制药有限公司4CYHS2500674盐酸艾司洛尔注射液广东南国药业有限公司4CYHS2500698盐酸奥普力农注射液山东健滨医药科技有限公司;西安汉丰药业有限责任公司3CYHS2500729盐酸半胱氨酸注射液北京柏雅联合药物研究所有限公司;广东星昊药业有限公司3CYHS2500743盐酸布比卡因注射液济南东方开元医药新技术有限公司;山东华鲁制药有限公司3CYHS2500708盐酸氮卓斯汀滴眼液武汉五景药业有限公司4CYHS2500721盐酸多巴胺注射液成都恒瑞制药有限公司;四川美大康佳乐药业有限公司3CYHS2500731盐酸多巴胺注射液成都恒瑞制药有限公司;四川美大康佳乐药业有限公司3CYHS2500732盐酸多奈哌齐口腔崩解片山东淄博新达制药有限公司4CYHS2500658盐酸甲氧氯普胺注射液江西人可医药科技有限公司;裕松源药业有限公司3CYHS2500693盐酸纳美芬注射液新乡市常乐制药有限责任公司3CYHS2500675盐酸纳美芬注射液新乡市常乐制药有限责任公司3CYHS2500673盐酸曲唑酮片江苏万高药业股份有限公司3CYHS2500737盐酸曲唑酮片江苏万高药业股份有限公司3CYHS2500738盐酸舍曲林口服溶液万特制药（海南）有限公司3CYHS2500677盐酸舍曲林口服溶液江苏润恒制药有限公司3CYHS2500685伊布替尼胶囊浙江诺得药业有限公司4CYHS2500657依折麦布阿托伐他汀钙片(Ⅰ)湖北午时药业股份有限公司4CYHS2500654依折麦布阿托伐他汀钙片(Ⅱ)湖北午时药业股份有限公司4CYHS2500653注射用硫酸多粘菌素B江苏迪赛诺制药有限公司3CYHS2500724注射用硫酸多粘菌素B广东金城金素制药有限公司;广东隆赋药业股份有限公司3CYHS2500722注射用乳糖酸红霉素海韬新药研发（江苏）有限公司;津药和平（天津）制药有限公司3CYHS2500734注射用头孢他啶阿维巴坦钠福安药业集团庆余堂制药有限公司4CYHS2500659注射用盐酸罗沙替丁醋酸酯湖北潜龙药业有限公司3CYHS2500692左卡尼汀注射液广州泽盛药业科技有限公司;珠海润都制药股份有限公司4CYHS2500687左卡尼汀注射液广州泽盛药业科技有限公司;珠海润都制药股份有限公司4CYHS2500686左西孟旦注射液仁合益康汇泽药业河北有限公司;河北仁合益康药业有限公司4CYHS2500707左氧氟沙星滴眼液安徽康融药业有限公司4CYHS2500715左乙拉西坦注射用浓溶液江苏润恒制药有限公司4CYHS2500671 4、新增一致性评价补充申报药品名称企业名称受理号多潘立酮片浙江昂利康制药股份有限公司CYHB2550104伏格列波糖片北京星昊医药股份有限公司CYHB2550110甲硝唑氯化钠注射液四川太平洋药业有限责任公司CYHB2550096甲硝唑氯化钠注射液四川美大康佳乐药业有限公司CYHB2550093门冬氨酸钾注射液辽宁药联制药有限公司CYHB2550094门冬氨酸钾注射液辽宁药联制药有限公司CYHB2550095头孢地尼片江苏亚邦强生药业有限公司CYHB2550107头孢地尼片江苏亚邦强生药业有限公司CYHB2550108维生素B12注射液山东齐都药业有限公司CYHB2550106维生素B6注射液江苏神龙药业有限公司;江苏吴中医药集团有限公司苏州制药厂CYHB2550109盐酸林可霉素注射液辰欣药业股份有限公司CYHB2550102叶酸片石药集团欧意药业有限公司CYHB2550105脂肪乳注射液(C14-24)西安力邦制药有限公司CYHB2550114脂肪乳注射液(C14-24)西安力邦制药有限公司CYHB2550112脂肪乳注射液(C14-24)西安力邦制药有限公司CYHB2550111脂肪乳注射液(C14-24)西安力邦制药有限公司CYHB2550113脂肪乳注射液(C14-24)四川科伦药业股份有限公司CYHB2550098脂肪乳注射液(C14-24)四川科伦药业股份有限公司CYHB2550099脂肪乳注射液(C14-24)四川科伦药业股份有限公司CYHB2550097注射用头孢他啶福建省福抗药业股份有限公司CYHB2550101注射用头孢他啶福建省福抗药业股份有限公司CYHB2550100注射用盐酸地尔硫卓苏州二叶制药有限公司CYHB2550103 数据来源：摩熵医药